Desmond James

MA Social Media Communications- @DCU Alumni
Account Executive @TrophicComms
Full-time writer, part-time daydreamer

[Desmond James @Des89James]

@michaelharriot Ion like dat

[Desmond James @Des89James]

“The diversity in our clinical trials must mirror the patient communities the treatment hopes to serve,”
Health equity innovation must go beyond the science - https://t.co/V6xFsP1wrM

[Desmond James @Des89James]

Well said... an investment in #diversity provides access to a wealth of untapped potential & future opportunities to innovate

[Brad Prosek @bprosek11]

Heard at @LS_Cares Impact Breakfast: “If we can invest 13 years in developing a drug, we must invest 13 years in developing girls with an interest in STEM”. +100%

[Desmond James @Des89James]

“In the last two-to-three years, the whole biotech environment has changed dramatically. In America, until last year, there were a lot of companies going public, and they didn’t need to do deals, so it was all on their own terms" https://t.co/cF908Z56bY

[Desmond James @Des89James]

While the pace of new #SPAC offerings seem to have slowed in the second quarter of 2021, they are still positioned as an attractive option for private #biotech & #pharma companies in need of rapid access to capital https://t.co/zrLI3qUTXz

[Desmond James @Des89James]

In 2020 biotech IPOs continued to break and establish new records, as more startups went public and raised more cash than ever before. In 2H of 2021, we saw the performance of biotech IPOs plummet. https://t.co/w6He2TOzSb via @BioPharmaDive

[Desmond James @Des89James]

So excited that I finally get to unveil my first solo website project. Thank you to the @TrophicComms team for trusting me to see it through and thank you to Ante and his team at @imagemakersmuc for helping me bring the vision to life.

[Trophic Communications @TrophicComms]

Our newly updated website is finally here! A big thank you to our long-term collaborator, @imagemakersmuc, for bringing our vision to life. Check out https://t.co/NioCgfMpEh to learn more about our capabilities as a strategic corporate #communications partner in the #lifesciences

[Desmond James @Des89James]

Congratulations to #Modra Pharmaceuticals on the announcement of Positive Phase 2b data evaluating it's lead candidate #ModraDoc006, an oral #taxane approach for patients living with #mCRPC https://t.co/DsI2ZsiAja

[Desmond James @Des89James]

Check out this great article from https://t.co/b5piPJ7knT on how companies such as @OsivaxVaccines are leading the charge in generating #universalvaccines that can protect the population from all current and future strands of #Covid19. https://t.co/kMGBcO9Fmy

[Desmond James @Des89James]

#Drugregulations present major challlenges for EU companies hoping for success in the US market. companies require a keen #commercialisation strategy, customizable to the needs of your specific drug. Check out this insightful piece in @pharmaphorum https://t.co/ETuJ7bx4A3

[Desmond James @Des89James]

So happy to be apart of this amazing team of communicators and celebrate Trophic's 4th #anniversary. I look forward to what the next year has in store!

[Trophic Communications @TrophicComms]

And of course we can not celebrate without one of our famous anniversary cakes!

[Desmond James @Des89James]

Check out this article on how the use of #socialmedia is defined by the value, relevance, & credibility of the content it conveys. https://t.co/Kkzwo4i7Ep

[Desmond James @Des89James]

A great article by @VirginiaGewin about the online initiative recognizing the contributions of black scientists and their increasing roles within the various areas of clinical research. Very proud to be #BlackinBiotech #diversity #inclusion

[nature @Nature]

Five researchers who organized and took part in the #BlackinSTEM weeks discuss their movements' impacts and rewards, including career opportunities, collaborations and meaningful institutional actions. https://t.co/HcSsKt8ayx

[Don Seiffert: @donseiffert.bsky.social @SeiffertDon]

“When you’re the VC, you’re kind of the kingmaker ... I felt like the entrepreneur needed someone to reach their hand out and say, ‘I’m going to help you with this.’” -- @cngarabedian. This week, @BosBizRowan reports on biotech's new funding models: https://t.co/P5KevGbO9r

[Desmond James @Des89James]

A strong team and a compelling #comunications strategy are vital for any #biotech looking to secure institutional #investors to raise their US value. https://t.co/q25VKlvGtR

[Desmond James @Des89James]

Great Article on how scientists and farmers are using social media to combat #misinformation posts. Platforms such as LinkedIn and Twitter can be valuable tools for #biotech professionals. https://t.co/VLAgBbm8ZK

[Desmond James @Des89James]

Great article from @FierceBiotech examining the efforts made by #biotech and #phama companies to make #DiversityandInclusion a priority and how information can be used in targeted programming and #SocialMedia outreach to achieve higher results. https://t.co/5ZP7rfZUJC

[Desmond James @Des89James]

In the wake of the Covid-19 pandemic, companies like @immatics were able to launch successful #IPOlistings, proving there is keen interest from investors in the #biotech space. Checkout the https://t.co/b5piPJ7knT article on whether this "trend" is potentially just the beginning

[Labiotech.eu @Labiotech_eu]

With record amounts of cash flowing into the #biotech industry, it’s natural to wonder when the funding window will close. According to Simon Goldman, @UCLTF's Investment Director, there’s little reason to assume this window will close at all. Here's why 👇🏻https://t.co/61YjBf6FuI

[Desmond James @Des89James]

As companies within the #biotech and #LifeSciences sectors start planning for their next fundraising efforts, the need for a firm like with #InvestorRelations capabilities like @TrophicComms is crucial.

[Trophic Communications @TrophicComms]

We provide a range of #IR services, from run-up to #IPO & #investor targeting based on peer analysis, to presentation training & developing financial communications. Visit https://t.co/qnN6qo5SMa for more on our IR/PR capabilities. #LifeSciences

[Desmond James @Des89James]

Today the #FDA determines the approval of #Aducanumab. @nytimes published a piece addressing the drug's pros and cons and two other treatment options that are showing promising data in case it is not approved. https://t.co/6wU4VzKoil